Stay updated with breaking news from Accucinch System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Designation Allows for Expedited Review of Transcatheter Therapy Designed to Improve Left Ventricular Structure and Function in Heart Failure Patients with Reduced Ejection Fraction
Designation Allows for Expedited Review of Transcatheter Therapy Designed to Improve Left Ventricular Structure and Function in Heart Failure Patients with Reduced Ejection FractionSANTA CLARA, Calif.--(BUSINESS WIRE)--#accucinch--Ancora Heart, Inc., a company developing a novel device-based therapy to address heart...
Ancora Heart announced today that it received FDA breakthrough device designation for its AccuCinch ventricular restoration system.
Ancora Heart Appoints Mark Miles as Chief Commercial Officer - read this article along with other careers information, tips and advice on BioSpace
Press release content from Business Wire. The AP news staff was not involved in its creation. Ancora Heart Enrolls First Patient in the CORCINCH-HF Study January 28, 2021 GMT As the only completely transcatheter procedure to treat the enlarged left ventricle, the AccuCinch® Ventricular Restoration System is a fundamentally different and innovative device-based therapy designed to improve the structure and function of the heart and help bring relief to HF patients who remain symptomatic despite current guideline-directed medical care. (Graphic: Business Wire) As the only completely transcathe...